KMT2A and acute myeloid leukemia: Its expression may regulate niche interactions and it was first described as LSC marker in chronic myeloid leukemia [110], but later shown to be also expressed on MLL-rearranged (MLLr) AML [70], specifically on the CD34+CD38− compartment.